

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 8, 2025

## Consolidated Financial Results for the Three Months Ended June 30, 2025 (Under Japanese GAAP)

Company name: Takara Bio Inc.  
 Listing: Tokyo Stock Exchange  
 Securities code: 4974  
 URL: <https://www.takara-bio.co.jp>  
 Representative: Tsuyoshi Miyamura, President & CEO  
 Inquiries: Noritaka Nishiwaki, Executive Officer, in charge of PR & IR Department

Telephone: +81-77-565-6970

Scheduled date to commence dividend payments: -

Preparation of supplementary material on quarterly financial results: Yes

Holding of quarterly financial results briefing: No

(Yen amounts are rounded down to millions, unless otherwise noted.)

### 1. Consolidated financial results for the three months ended Jun. 30, 2025 (from Apr. 1, 2025 to Jun. 30, 2025)

#### (1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended Jun. 30, 2025	9,266	9.1	(1,796)	-	(1,838)	-	(1,511)	-
Jun. 30, 2024	8,493	(7.4)	(1,634)	-	(1,498)	-	(1,047)	-

Note: Comprehensive income For the three months ended Jun. 30, 2025: (¥4,366 million) -  
 For the three months ended Jun. 30, 2024: ¥1,778 million 119.3%

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
Jun. 30, 2025	(12.55)	-
Jun. 30, 2024	(8.70)	-

#### (2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	yen
Jun. 30, 2025	129,943	109,436	84.0	905.93
Mar. 31, 2025	125,334	115,849	92.2	959.19

Reference: Equity

As of Jun. 30, 2025: ¥109,087 million

As of Mar. 31, 2025: ¥115,500 million

## 2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended Mar. 31, 2025	-	0.00	-	17.00	17.00
Fiscal year ending Mar. 31, 2026	-				
Fiscal year ending Mar. 31, 2026 (Forecast)		0.00	-	17.00	17.00

Note: Revisions to the forecast of cash dividends most recently announced: None

## 3. Consolidated financial forecast for the year ending March 31, 2026 (Apr. 1, 2025 – Mar. 31, 2026)

(Percentages indicate year-on-year changes for the full year and year-on-year changes for the quarter.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
Second quarter (cumulative)	21,300	7.8	(1,450)	-	(1,430)	-	(1,320)	-	(10.96)
Full-year	52,500	16.6	2,500	10.5	2,500	(3.6)	1,300	24.8	10.08

Note: Revisions to the financial forecast since the most recent announced: None

### \* Notes

- (1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): Yes  
 Newly included: 1 companies (Curio Bioscience, Inc.)  
 Excluded: - companies (Company name)  
 (NOTE) For details, please refer to "(4) Notes to Consolidated Quarterly Financial Statements (Business Combinations)" of "2. Consolidated Quarterly Financial Statements and Primary Notes" on page 9 of the attached document.
- (2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None
- (3) Changes in accounting policies, changes in accounting estimates, and restatement
  - (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
  - (ii) Changes in accounting policies due to other reasons: None
  - (iii) Changes in accounting estimates: None
  - (iv) Restatement: None
- (4) Number of issued shares (common shares)

- (i) Total number of issued shares at the end of the period (including treasury shares)

As of Jun. 30, 2025	120,415,600 shares
As of Mar. 31, 2025	120,415,600 shares

- (ii) Number of treasury shares at the end of the period

As of Jun. 30, 2025	113 shares
As of Mar. 31, 2025	113 shares

- (iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended Jun. 30, 2025	120,415,487 shares
Three months ended Jun. 30, 2024	120,415,600 shares

- \* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

\* Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Inc. (the “Company”) based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to “1. Overview of Financial Results for the Three Months ended June 30, 2025 (4) Explanation of Consolidated Financial Forecasts and Other Forward-looking Statements” on page 3 of the attached document.

## Contents of the attached document

1. Overview of Financial Results for the Three Months Ended June 30, 2025 .....	2
(1) Overview of Financial Results.....	2
(2) Overview of Financial Position for the Current Quarter.....	2
(3) Overview of Cash Flows for the Current Quarter.....	2
(4) Explanation of Consolidated Financial Forecasts and Other Forward-looking Statements.....	3
2. Consolidated Quarterly Financial Statements and Primary Notes.....	4
(1) Consolidated Quarterly Balance Sheets.....	4
(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income.....	6
(Consolidated Quarterly Statements of Profit or Loss).....	6
(Consolidated Quarterly Statements of Comprehensive Income).....	7
(3) Consolidated Quarterly Statements of Cash Flows.....	8
(4) Notes to Consolidated Quarterly Financial Statements.....	9
(Notes on Premise of Going Concern).....	9
(Notes in case of Changes in Marked Amount of Shareholders' Equity).....	9
(Notes on Segment Information).....	9
(Business Combination).....	9
3. Supplementary Information.....	12
(1) Trends in Key Indicators for Business Management.....	12
(2) Comparative Consolidated Statement of Income.....	13

## **1. Overview of Financial Results for the Three Months ended June 30, 2025**

### **(1) Overview of Financial Results**

The outlook for the global economy during the three months ended June 30, 2025 is uncertain due to factors such as prolonged inflation in the United States and Europe, economic recession in China, and heightened geopolitical risks caused by regional conflicts and other factors, and the ongoing blocking of the global economy.

In the life science industry as well, the research budget has been reduced due to the impact of high prices and high interest rates. In the United States, the government policy has substantially reduced research grants, and the activity of research and development in the industry and academia is declining. This has led to a growing sense of uncertainty about the future.

Under these circumstances, in the Long-Term Management Plan 2026 for the six-year period ending March 31, 2026, and the Medium-Term Management Plan 2026 for the three-year period ending March 31, 2026, we have promoted the development of basic biotechnology-based biologics development technologies through Reagents / Instruments business and CDMO business and have promoted initiatives aimed at becoming a global platform provider responsible for the infrastructure of the life science industry.

For the three months ended June 30, 2025, net sales increased to ¥9,266 million (up 9.1% year-on-year) as a result of year-on-year increase in Reagents, CDMO and Gene Therapy categories. Cost of sales increased to ¥4,262 million (up 3.0% year-on-year) due to changes in the sales mix and other factors. As a result, gross profit increased to ¥5,003 million yen (up 14.9% year-on-year). Selling, general and administrative expense amounted to ¥6,800 million (up 13.6% year-on-year) due to the acquisition of Curio Bioscience, Inc. (“Curio”) and the recording of goodwill amortization. As a result, operating loss was ¥1,796 million (compared with an operating loss of ¥1,634 million in the same period of the previous fiscal year).

As a result of the expansion of operating loss, the ordinary loss was ¥1,838 million (compared with an ordinary loss of ¥1,498 million in the same period of the previous fiscal year) and loss before income taxes was ¥1,782 million (compared with a loss before income taxes of ¥1,507 million in the same period of the previous fiscal year), resulting in income tax-deferred of minus ¥538 million. As a result, the net loss attributable to owners of parent was ¥1,511 million (compared with net loss attributable to owners of parent of ¥1,047 million in the same period of the previous fiscal year).

### **(2) Overview of Financial Position for the Current Quarter**

Total assets at the end of the three months ended June 30, 2025 were ¥129,943 million, an increase of ¥4,608 million from the end of the previous fiscal year. This was mainly due to increase of ¥10,971 million in technical assets and ¥6,147 million in goodwill following the acquisition of Curio, despite decrease of ¥7,543 million in cash and deposits, 4,447 million in notes and accounts receivable-trade, and ¥861 million in investments and other assets.

Total liabilities at the end of the three months ended June 30, 2025 were ¥20,506 million, an increase of ¥11,021 million from the end of the previous fiscal year. This was mainly due to increases of ¥8,628 million in other non-current liabilities and ¥2,599 million in other current liabilities. The increase in other non-current liabilities and other current liabilities was mainly due to the recognition of contingent consideration from the acquisition of Curio.

Total net assets at the end of the three months ended June 30, 2025 were ¥109,436 million, a decrease of ¥6,413 million from the end of the previous fiscal year. This was mainly due to decrease of ¥2,863 million in foreign currency translation adjustment by the appreciation of the yen and ¥3,558 million in retained earnings.

### **(3) Overview of Cash Flows for the Current Quarter**

Net cash provided by operating activities amounted to ¥1,912 million, a decrease of ¥2,621 million compared with the same period of the previous fiscal year. This was mainly due to cash inflow from ¥4,287 million in decrease of notes and accounts receivable-trade and ¥1,046 million in depreciation and amortization, and cash outflow of ¥1,782 million in a quarterly loss before income taxes and ¥1,484 million in increase of inventories.

Net cash used in investing activities amounted ¥6,880 million, an increase of ¥6,088 million compared with the same period of the previous fiscal year, mainly due to the purchase of shares of subsidiaries resulting in a change in the scope of consolidation of ¥6,524 million.

Net cash used in financing activities was ¥2,030 million, mainly due to cash dividends paid of ¥1,980 million, an increase of ¥7 million compared with the same period of the previous fiscal year.

As a result of the above, the balance of cash equivalents at the end of the three months ended June 30, 2025, including the effect of exchange rate change on cash and cash equivalents, decreased by ¥7,439 million from the end of the previous fiscal year to ¥19,596 million.

#### **(4) Explanation of Consolidated Financial Forecasts and Other Forward-looking Statements**

Results for the three months ended June 30, 2025 under the review were largely in line with the forecasts announced on May 13, 2025. As mentioned above, uncertainty in the life sciences industry is increasing, and it is difficult to forecast the future. However, at this point, the Company's forecasts for business results from the second quarter onward are generally in line with these forecasts.

Consolidated earnings forecasts for the fiscal year ending March 31, 2026 are net sales of ¥52,500 million, operating profit of ¥2,500 million, ordinary income of ¥2,500 million, and net income attributable to owners of the parent of ¥1,300 million. The Company expects net sales, operating profit, and net income attributable to owners of the parent to increase both sales and profits year on year. For the second quarter of the fiscal year under review, the Company forecasts net sales of ¥21,300 million, operating loss of ¥1,450 million, ordinary loss of ¥1,430 million, and net loss attributable to owners of the parent of ¥1,320 million, and forecasts an increase in sales and a decrease in each profit item compared with the same period of the previous fiscal year.

As mentioned above, there is a bias in the progress of net sales in the second quarter of the fiscal year under review. Therefore, the forecast for operating profit is based on the projected loss for the first, second and third quarters of the fiscal year under review, and the forecast is for operating profit of ¥2,500 million for the full year.

## 2. Consolidated Quarterly Financial Statements and Primary Notes

### (1) Consolidated Quarterly Balance Sheets

(Millions of yen)

	As of Mar. 31, 2025	As of Jun. 30, 2025
<b>Assets</b>		
Current asset		
Cash and deposits	29,549	22,006
Notes and accounts receivable-trade	14,095	9,647
Merchandise and finished goods	6,794	8,037
Work in process	1,070	1,190
Raw materials and supplies	4,575	4,400
Other	1,672	1,748
Allowance for doubtful accounts	(77)	(92)
Total current assets	57,679	46,938
Non-current assets		
Property, plant and equipment		
Buildings and structures	30,194	29,802
Accumulated depreciation	(9,771)	(9,881)
Buildings and structures, net	20,422	19,921
Machinery, equipment and vehicles	9,075	8,813
Accumulated depreciation	(6,051)	(5,933)
Machinery, equipment and vehicles, net	3,024	2,879
Tools, furniture and fixtures	12,129	12,008
Accumulated depreciation	(8,550)	(8,503)
Tools, furniture and fixtures, net	3,578	3,505
Land	9,250	9,046
Construction in progress	19,450	19,553
Others	2,203	2,208
Accumulated depreciation	(975)	(1,016)
Others, net	1,227	1,191
Total Property, plant and equipment	56,954	56,097
Intangible assets		
Goodwill	6,516	12,663
Technology-based intangible assets	112	11,083
Other	1,342	1,291
Total intangible assets	7,971	25,038
Investments and other assets		
Investments and other assets	2,730	1,868
Total investments and other assets	2,730	1,868
Total non-current assets	67,655	83,004
<b>Total assets</b>	<b>125,334</b>	<b>129,943</b>

(Millions of yen)

	As of Mar. 31, 2025	As of Jun. 30, 2025
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable-trade	1,652	1,389
Accrued income taxes	213	81
Provision for bonuses	1,003	1,190
Other	4,261	6,860
Total current liabilities	7,131	9,522
Non-current liabilities		
Retirement benefit liabilities	989	992
Other	1,363	9,992
Total non-current liabilities	2,353	10,984
Total liabilities	9,485	20,506
<b>Net assets</b>		
Shareholders' equity		
Share capital	14,965	14,965
Capital surplus	32,893	32,893
Retained earnings	52,465	48,907
Treasury stock	(0)	(0)
Total shareholders' equity	100,324	96,766
Accumulated other comprehensive income		
Foreign currency translation adjustment	15,331	12,467
Cumulative remeasurements of retirement benefit	(155)	(145)
Total accumulated other comprehensive income	15,175	12,321
Non-controlling interests	348	348
Total net assets	115,849	109,436
Total liabilities and net assets	125,334	129,943



**(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income**

**(Consolidated Quarterly Statements of Profit or Loss)**

(Millions of yen)

	Three months ended Jun. 30, 2024	Three months ended Jun. 30, 2025
Net sales	8,493	9,266
Cost of sales	4,139	4,262
Gross profit	4,353	5,003
SG&A expenses		
Employees' salaries and bonuses	1,757	1,817
Retirement benefit expenses	87	83
R&D expenses	1,706	1,787
Provision of allowance	257	193
Other	2,178	2,919
Total SG&A expenses	5,988	6,800
Operating profit (loss)	(1,634)	(1,796)
Non-operating income		
Interest income	73	50
Foreign exchange gains	26	-
Rent income from real estate	39	40
Other	38	14
Total non-operating income	178	105
Non-operating expense		
Interest expenses	7	117
Foreign exchange losses	-	5
Rent expenses on real estate	15	22
Other	19	1
Total non-operating expenses	42	147
Ordinary profit (loss)	(1,498)	(1,838)
Extraordinary gains		
Gain on sale of fixed assets	2	29
Gain on reversal of asset retirement obligations	-	53
Other	-	0
Total extraordinary profit	2	83
Extraordinary losses		
Loss on sale and retirement of non-current assets	11	3
Loss on extinguishment of tie-in shares	-	24
Total extraordinary losses	11	27
Income (loss) before income taxes and others	(1,507)	(1,782)
Income taxes-current	210	249
Income taxes-deferred	(686)	(538)
Total income taxes	(475)	(289)
Net income (loss)	(1,032)	(1,492)
Net income attributable to non-controlling interest	15	18
Net income (loss) attributable to owners of the parent	(1,047)	(1,511)

**(Consolidated Quarterly Statements of Comprehensive Income)**

(Millions of yen)

	Three months ended Jun. 30, 2024	Three months ended Jun. 30, 2025
Net income	(1,032)	(1,492)
Other comprehensive income		
Foreign currency translation adjustment	2,793	(2,882)
Remeasurements of retirement benefit	17	9
Total other comprehensive income	2,811	(2,873)
Comprehensive income	1,778	(4,366)
Comprehensive income attributable to:		
Owners of the parent	1,745	(4,365)
Non-controlling interest	33	(0)

### (3) Consolidated Quarterly Statements of Cash Flows

(Millions of yen)

	Three months ended Jun. 30, 2024	Three months ended Jun. 30, 2025
Net cash provided by (used in) operating activities		
Loss before income taxes and others	(1,507)	(1,782)
Depreciation and amortization	927	1,046
Depreciation and amortization on other	42	42
Amortization of goodwill	169	272
Increase (decrease) in allowance for doubtful accounts	2	18
Increase (decrease) in reserve for bonuses	384	214
Increase (decrease) in retirement benefit liabilities	17	3
Interest income	(73)	(50)
Interest expenses	7	117
Loss (gain) on sale and retirement of fixed assets	9	(26)
Loss (gain) on extinguishment of tie-in shares	-	24
Gain on reversal of asset retirement obligations	-	(53)
Decrease (increase) in trade receivables-trade	4,132	4,287
Decrease (increase) in inventories	(640)	(1,484)
Increase (decrease) in notes and accounts payable-trade	5	(249)
Increase (decrease) in consumption taxes payable	1,478	(50)
Increase (decrease) in other current liabilities	(331)	(176)
Other	(37)	(63)
Subtotal	4,588	2,089
Interest and dividend income received	58	58
Income expenses paid	(7)	(4)
Income taxes paid	(103)	(230)
Net cash provided by (used in) operating activities	4,534	1,912
Net cash provided by (used in) investing activities		
Payments into time deposits	(375)	(977)
Proceed from withdrawal of time deposits	364	948
Purchase of property, plant and equipment and intangible assets	(572)	(377)
Proceeds from sales of property, plant and equipment and intangible assets	3	30
Purchase of other depreciable assets	(212)	(0)
Purchase of shares of subsidiaries resulting in change in scope of consolidation	-	(6,524)
Other	(0)	20
Net cash provided by (used in) investing activities	(792)	(6,880)
Net cash provided by (used in) financing activities		
Dividends paid	(1,971)	(1,980)
Repayments of lease obligations	(51)	(50)
Net cash provided by (used in) financing activities	(2,022)	(2,030)
Effect of exchange rate change on cash and cash equivalents	708	(490)
Net increase (decrease) in cash and cash equivalents	2,427	(7,489)
Cash and cash equivalents at beginning of period	33,171	27,036
Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries	-	49
Cash and cash equivalents at end of period	35,599	19,596

#### **(4) Notes to Consolidated Quarterly Financial Statements**

##### **(Notes on Premise of Going Concern)**

No items to report.

##### **(Notes in case of Changes in Marked Amount of Shareholders' Equity)**

No item to report.

##### **(Notes on Segment Information)**

Since our group is a single segment, the description is omitted.

##### **(Business combinations)**

##### **(Business combination through acquisition)**

##### **(Acquisition of Curio Bioscience, Inc.)**

On January 15, 2025 (U.S. local time), Takara Bio USA Holdings Inc., a 100% owned subsidiary of the Company, entered into a purchase agreement with Curio Bioscience, Inc. ("Curio") stockholder representatives and acquired the shares of Curio and made it a subsidiary.

#### **(1) Outline of the business combination**

##### **1) Name of the acquired company, description of business**

Name of the acquired company: Curio Bioscience, Inc.

Description of business: Development, manufacturing, and sales of research reagents for spatial analysis

##### **2) Main reasons for the business combination**

Our group provides research reagents, scientific instruments, and CDMO services for biotechnology researchers in academia and companies. Among other things, by focusing its efforts on the development and sale of products of reagents related to next-generation sequencing ("NGS"), the Group has been expanding the scale of its sales mainly in the U.S. in recent years. Technology is making rapid progress in the field of NGS. The growth of the NGS market is expected to be shifting from simple NGS analysis to single-cell analysis and further to spatial transcriptome analysis ("spatial analysis"). The Group launched a single-cell analysis system in 2017 and started contract services for spatial analysis in 2023. In such ways, the Group aims at business development grasping trends in the NGS market.

Curio is a venture-based company in the U.S. that develops advanced reagents for spatial analysis. It provides reagents that enable spatial analysis of high density and high resolution by using DNA bar code beads, which are its unique technology. By making Curio a member of our Group this time, the Group will produce high synergy effects through combining Curio's basic technology for spatial analysis with genetic engineering technology and genetic analysis technology that the Group has fostered. Specifically, the Group will promote development of general-purpose reagents which conform to various single-cell analyzers, development of quality products by combining Curio's products and the Company's products and differentiation of them from competitive products, as well as expansion of CDMO services for spatial analysis using Curio's products.

##### **3) Date of business combination**

January 15, 2025 (U.S. local time)

##### **4) Legal form of the business combination**

Acquisition of shares

##### **5) Name of company after the business combination**

Curio Bioscience, Inc.

##### **6) Ratio of voting rights acquired**

100%

- 7) Main grounds for deciding the company to acquire  
Acquisition of shares in consideration of cash

**(2) Period of the results of the acquired company included in the consolidated quarterly financial statements**  
January 15, 2025 through March 31, 2025

**(3) Acquisition cost of the acquired company and breakdown by type of consideration**

Acquisition cost	US\$ 107.4 million
------------------	--------------------

Breakdown by type of consideration:

Cash	US\$ 40.9 million
------	-------------------

Contingent consideration (unpaid portion) (Note)	US\$ 66.4 million
--	-------------------

(NOTE) The Company has contingent consideration arrangements that provide for additional consideration upon the achievement of multiple development and sales milestones up to an aggregate of US\$ 150 million. Our group estimated the likelihood of achieving the milestones and determined it at its present value and recognized US\$ 66.4 million as accrued acquisition consideration.

Of the change in fair value related to contingent consideration, the Company will record the portion of the change based on time value in “Interest expense” and the portion of change based on other than time value in “SG&A expenses.”

**(4) Details and amount of major acquisition-related expenses**

Advisory fees and commissions:	US\$ 4,309,000
--------------------------------	----------------

**(5) Goodwill, reason for recognizing goodwill, amortization method and amortization term**

1) Goodwill amount	¥6,973 million (US\$ 44.2 million)
--------------------	------------------------------------

2) Reason for recognizing goodwill	This is mainly due to the expected future excess profitability of future business development
------------------------------------	---

3) Method and term to amortize goodwill	Straight-line method over 18 years
---	------------------------------------

(NOTE) The amount of goodwill is provisionally calculated based on the information available at the present time, as the allocation of acquisition costs has not been completed at the end of the current quarterly consolidated accounting period.

**(6) The amount of assets accepted and liabilities assumed on the date of the Business Combination, and major breakdown thereof**

Current assets	¥278 million	(US\$ 1.7 million)
----------------	--------------	--------------------

Fixed assets	¥18,892 million	(US\$ 119.8 million)
--------------	-----------------	----------------------

Total assets	¥19,170 million	(US\$ 121.6 million)
--------------	-----------------	----------------------

Current liabilities	¥723 million	(US\$ 4.5 million)
---------------------	--------------	--------------------

Long-term liabilities	¥11,990 million	(US\$ 76 million)
-----------------------	-----------------	-------------------

Total liabilities	¥12,713 million	(US\$ 80.6 million)
-------------------	-----------------	---------------------

(NOTE) The amount of assets accepted and liabilities assumed are provisionally calculated based on information available at the present time, as the allocation of acquisition cost has not been completed at the end of the current quarter.

**(7) Amount allocated to intangible assets other than goodwill, its breakdown by major type, and the weighted average amortization period for the total amount and major type**

Type	Amount	Weighted-average amortization period
------	--------	--------------------------------------

Technology assets	¥11,755 million (US\$ 74.6 million)	18 years
-------------------	-------------------------------------	----------

(NOTE) The amount allocated to intangible assets other than goodwill is provisionally calculated based on the information available at the present time, as the allocation of acquisition costs has not been completed at the end of the current quarter.

**(8) Estimated amount and calculation method of the impact on the consolidated statement of income for the current quarter on the assumption that the business combination has been completed on the day of commencement of the consolidated fiscal year**

Disclosure is omitted because the amount is immaterial.

### 3. Supplemental Information

#### (1) Trends in Key Indicators for Business Management

##### 1) Cash Flows

(Millions of yen)

	Three months ended Jun. 30, 2024 (Apr. 1, 2024 – Jun. 30, 2024)	Three months ended Jun. 30, 2025 (Apr. 1, 2025 – Jun. 30, 2025)	Year ended Mar. 31, 2025 (Apr. 1, 2024 – Mar. 31, 2025)
Cash flow from operating activities	4,534	1,912	5,844
Cash flow from investing activities	(792)	(6,880)	(10,912)
Cash flow from financing activities	(2,022)	(2,030)	(2,256)

##### 2) Sales Breakdown by Region

(Millions of yen)

	Three months ended Jun. 30, 2024 (Apr. 1, 2024 – Jun. 30, 2024)	Three months ended Jun. 30, 2024 (Apr. 1, 2025 – Jun. 30, 2025)	Year ended Mar. 31, 2025 (Apr. 1, 2024 – Mar. 31, 2025)
Japan	2,212	2,454	15,062
United States	3,148	3,037	12,997
China	1,355	1,153	8,522
Asia excluding Japan and China	709	718	2,855
Europe	979	1,807	5,248
Others	88	95	353
Total	8,493	9,266	45,039

## (2) Comparative Consolidated Statement of Income

(Rounded down to one million yen)

	Three months ended Jun. 30, 2024	Three months ended Jun. 30, 2025	Y/Y change	Y/Y ratio
(Net sales)				
Reagents	6,606	6,986	379	5.7%
Instruments	221	173	(47)	(21.6%)
CDMO	1,018	1,178	160	15.8%
Gene Therapy	647	927	280	43.3%
Total net sales	8,493	9,266	772	9.1%
(Operating profit and Loss)				
<b>Net sales</b>	8,493	9,266	772	9.1%
Cost of sales	4,139	4,262	122	3.0%
Gross profit	4,353	5,003	649	14.9%
SG & A expenses	5,988	6,800	811	13.6%
Transportation expenses	136	127	(9)	(6.8%)
Advertising expenses	16	28	12	73.1%
Promotion expenses	175	212	37	21.3%
R&D expenses	1,706	1,787	80	4.7%
Administrative expense, other	3,888	4,583	695	17.9%
Enterprise taxes (external standards taxation)	65	61	(4)	(6.5%)
<b>Operating profit</b>	(1,634)	(1,796)	(161)	—
(Non-operating income and Expenses)				
Non-operating income	178	105	(72)	(40.8%)
Non-operating expenses	42	147	104	247.8%
<b>Ordinary profit</b>	(1,498)	(1,838)	(339)	—
(Extraordinary income and Losses)				
Extraordinary income	2	83	80	—
Extraordinary losses	11	27	15	135.8%
Income before income taxes and others	(1,507)	(1,782)	(274)	—
Income taxes	(475)	(289)	186	—
Net income	(1,032)	(1,492)	(460)	—
Net income (loss) attributable to non-controlling interests	15	18	3	22.0%
<b>Net income attributable to owners of the parent</b>	(1,047)	(1,511)	(463)	—
Depreciation and amortization (Property, plant and equipment and intangible assets)	927	1,046	119	12.8%
Amortization of goodwill	169	272	103	61.2%